First Pacific Advisors LP Buys Shares of 741,332 Maravai LifeSciences Holdings, Inc. $MRVI

First Pacific Advisors LP bought a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 741,332 shares of the company’s stock, valued at approximately $1,787,000. First Pacific Advisors LP owned 0.29% of Maravai LifeSciences as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of MRVI. VELA Investment Management LLC raised its holdings in shares of Maravai LifeSciences by 5.6% during the 1st quarter. VELA Investment Management LLC now owns 156,334 shares of the company’s stock valued at $345,000 after purchasing an additional 8,222 shares in the last quarter. Callan Family Office LLC bought a new position in shares of Maravai LifeSciences during the 2nd quarter valued at $25,000. Ethic Inc. bought a new position in shares of Maravai LifeSciences during the 2nd quarter valued at $26,000. Performa Ltd US LLC raised its holdings in shares of Maravai LifeSciences by 245.0% during the 1st quarter. Performa Ltd US LLC now owns 17,250 shares of the company’s stock valued at $38,000 after purchasing an additional 12,250 shares in the last quarter. Finally, McAdam LLC bought a new position in shares of Maravai LifeSciences during the 1st quarter valued at $31,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on MRVI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Royal Bank Of Canada cut their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, August 12th. Three research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.22.

Maravai LifeSciences Stock Performance

NASDAQ:MRVI opened at $3.23 on Wednesday. The firm’s 50-day moving average is $2.87 and its 200-day moving average is $2.48. Maravai LifeSciences Holdings, Inc. has a 52-week low of $1.66 and a 52-week high of $8.29. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.49 and a current ratio of 5.16. The company has a market cap of $824.81 million, a price-to-earnings ratio of -2.37 and a beta of 0.33.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.